key: cord-0738373-71zyd9uq
authors: Nielsen, Marisa C.; Machado, Rafael R.G.; Mitchell, Brooke M.; McConnell, Allan J.; Saada, Nehad I.; Weaver, Scott C.; Ren, Ping
title: A comparison of Seegene Technologies Novaplex SARS-CoV-2 Variants I, II, & IV assays with spike gene sequencing for detection of known SARS-CoV-2 variants
date: 2022-02-24
journal: J Mol Diagn
DOI: 10.1016/j.jmoldx.2022.02.001
sha: 974e3d3f3dceaf265bb25231d9d022db43455c2b
doc_id: 738373
cord_uid: 71zyd9uq

Tracking new and emerging SARS-CoV-2 variants has become increasingly important for public health responses, mainly because of variant-dependent transmission, disease severity, and treatment decisions. This evaluation compared Seegene Technologies Novaplex SARS-CoV-2 Variant I, II, and IV (I,II&IV) assays to detect known SARS-CoV-2 variants using traditional spike gene Sanger sequencing results as the gold standard reference. Both RNA extraction and extraction-free protocols were assessed. A total of 156 samples were included in this study. There was 100% (109/109) overall agreement (95% CI: 96.7 - 100%) between the spike gene sequencing and the I,II&IV results using extracted RNA for the variants included in the Novaplex assay menus. The RNA extraction-free method was 91.7% (143/156) as sensitive (95% CI: 86.2 - 95.5%) as the traditional RNA extraction method. Using the extraction-free method on samples with higher Ct values (>30) resulted in some mutations not being detected, presumably due to lower nucleic acid concentrations in the original samples. In conclusion, the I,II&IV assays provide an accurate, rapid, and less labor-intensive method for detecting SARS-CoV-2 and identifying known variants of interest and concern. The RNA extraction-free method for samples with Ct lower than 30 could be cost-effective for surveillance purposes. However, spike gene sequencing retains the advantage of detecting more and new variants.

Tracking new and emerging SARS-CoV-2 variants has become increasingly important for public 23 health responses, mainly because of variant-dependent transmission, disease severity, and treatment 24 decisions. This evaluation compared Seegene Technologies Novaplex SARS-CoV-2 Variant I, II, and IV 25 (I,II&IV) assays to detect known SARS-CoV-2 variants using traditional spike gene Sanger sequencing 26 results as the gold standard reference. Both RNA extraction and extraction-free protocols were assessed. 27

A total of 156 samples were included in this study. There was 100% (109/109) overall agreement (95% CI: 28 96.7 -100%) between the spike gene sequencing and the I,II&IV results using extracted RNA for the 29 variants included in the Novaplex assay menus. The RNA extraction-free method was 91.7% (143/156) as 30 sensitive (95% CI: 86.2 -95.5%) as the traditional RNA extraction method. Using the extraction-free 31 method on samples with higher Ct values (>30) resulted in some mutations not being detected, 32 presumably due to lower nucleic acid concentrations in the original samples. In conclusion, the I,II&IV 33 assays provide an accurate, rapid, and less labor-intensive method for detecting SARS-CoV-2 and 34 identifying known variants of interest and concern. The RNA extraction-free method for samples with Ct 35

proportions, https://www.gisaid.org/hcov19-variants/, last accessed October 15, 2021). Delays in 48 genomic sequencing results could negatively impact mitigation efforts. Therefore, rapid variant detection 49 is a crucial tool for impact assessment and implementation of control measures. 50

Currently, SARS-CoV-2 variants are monitored by spike (S) gene sequencing or whole-genome 51 sequencing (WGS). S gene sequencing is the most widely used and can detect mutations that may affect 52 antibody binding and Angiotensin-converting enzyme 2 (ACE2) receptor affinity in the human body 1 . 53 These mutations have been used to characterize the known variants. According to the Centers for Disease 54

Control and Prevention (CDC), variants are described as follows: variants of interest (VOIs), variants of 55 concern (VOCs), variants of high consequence (VOHCs), and variants being monitored (VBMs) 56 In this study, Seegene Technologies Novaplex SARS-CoV-2 Variant I, II, and IV (I,II&IV) assays 68 were compared with S gene sequencing for the detection of known SARS-CoV-2 variants. Additionally, 69 extraction-free, heat-released RNA were investigated. S gene sequencing can detect all known variants, 71 while the I,II&IV assays, which rely on multiplex RT-PCR technology, simultaneously confirm the 72 presence of SARS-CoV-2 by detecting the RNA-dependent RNA polymerase gene (RdRp) Scientific, Waltham, MA) and stored at -80C overnight. The next day, samples were thawed, vortexed, 103 and 266.6 µl of chloroform was added. Samples were centrifuged at 12,500 x g for 15 min at 4C to 104 separate the phases. The top aqueous phase (500 µl) was aspirated and added to 667 µl of isopropanol 105 containing 2 µl of GlycoBlue Coprecipitant (Invitrogen; Thermo Fisher Scientific, Waltham, MA), vortexed 106 for 10 seconds. Samples were incubated at room temperature for 10 minutes and centrifuged at 20,800 107

x g for 20 minutes at 4C to pellet RNA. Isopropanol was removed, 1 ml of 75% ethanol was added, and 108 samples were vortexed and inverted several times. RNA was precipitated by centrifugation at 10,000 x g 109 for 10 minutes at 4C. Ethanol was removed, and the pellet was allowed to air-dry for 5-10 minutes. The 110 RNA pellet was then resuspended in 20 µl of RNase/DNase-free water. 111 112 Extraction free method 113

Fifteen µl of VTM for each sample was added to 45 µl of nuclease-free molecular grade water in 114 PCR tubes. The tubes were capped, quickly vortexed, and briefly centrifuged. These were then placed on 115 a thermocycler and incubated at 98°C for 3 min, then cooled to 4°C for 5 min. The samples were used 116 immediately for the I,II&IV assays.

The Novaplex SARS-CoV-2 Variants I, II, and IV Assays (Seegene Technologies, Walnut Creek, CA) 120

were performed according to the manufacturer's instructions using the CFX96 Touch Real-Time PCR 121

Detection System (Bio-Rad, Hercules, CA, USA). In brief, a 20 µl reaction was assembled through the 122 addition of 5µl of RNA (extracted or extraction-free) from each sample and 15µl of the manufacturer-123 provided master mix. The PCR protocol was defined by the manufacturer and programmed into the 124 software as follows: (i) 50°C, 20 min; 95°C, 15 min; (ii) 95°C, 10s; 60°C, 40s; 72°C, 20s; 3 cycles; (iii) 95°C, 125 10s; 60°C, 15s; 72°C, 10s; 42 cycles; (iv) indefinite hold at 4°C. The test results were analyzed with the 126 Seegene software and displayed with the Seegene viewer on the monitor. Table 1 The numerical values of sensitivity and specificity were represented as the proportion (%) of true 152 positives and negatives, respectively, that were correctly identified by the evaluated tests when compared 153 to the Sanger sequences. Furthermore, 95% confidence intervals (CI) were calculated around proportions. 154

The Ct values, a continuous variable, were expressed by boxplots showing medians (middle line) and third 155 and first quartiles (boxes), while the whiskers showed maximum and minimum range above and below 156 the box. The comparisons between groups were performed with the unpaired, two-sided Mann-Whitney 157 U test. All values with p <0.05 were considered significant (GraphPad Prism version 9.0.1, GraphPad 158 Software, San Diego, CA, USA). 159 160

A total of 156 samples were processed with RNA extraction and extraction-free methods. Of 162 those, 109 (109/156) were variants that were identifiable by the I,II&IV assays. There was 100% (109/109) 163 overall agreement (95% CI 96.7 -100%) between the I,II &IV assays and S gene sequencing ( RT-PCR yielded an undetectable band upon gel electrophoresis) but were detected by the I,II&IV assays. 171

Out of the 156 samples, only 17 were identified as wild-type by S gene sequencing (Table 2 ). In addition, 172 37 samples had mutations detected by S gene sequencing but not detectable by the I,II&IV assays (Table  173 4). Supplementary Table S1 lists all the mutations detected by S gene sequencing for these 37 samples. 174

They could not be defined as true wild-type because of these existing mutations. Taking these data 175 together and analyzing each substitution individually in the 146 samples with S gene sequencing results, 176 both the sensitivities and specificities for all the targets on the I,II&IV assays testing menus were 100%. 177

Supplementary Table S2 provides more detailed information on the sensitivity and specificity of each 178 mutation detected by the I,II&IV assays. 179

Additionally, the two different extraction protocols (chloroform-ethanol RNA extraction and 180 extraction-free, heat-release method) were compared using the I,II&IV assays. Overall, there was a 91.7% 181 (143/156) agreement (95% CI 86.2 -95.5%) between the two ( Table 5) on the I,II&IV assays testing menus but detected by S gene sequencing, the I,II&IV assays did not call out 198 the wrong mutations, indicating the assays were very specific. 199

The extraction-free RNA isolation protocol proved to be a time-saving alternative to standard 200 chloroform-ethanol RNA extraction for samples with Ct values below 30. It could help us get the results 201 at least one day sooner. A major limiting factor for molecular SARS-CoV-2 assays is the lack of availability 202 of RNA extraction reagents, and conventional extraction remains a time-consuming part of molecular 203 diagnosis of SARS-CoV-2. Extraction-free methods have become a reliable high-throughput diagnostic 204 approach 9-13 . According to the CDC COVID-19 Breakthrough Case Investigations and Reporting, 205 sequencing is recommended only for samples with a Ct value ≤ 28.0, since sequencing is not feasible with 206

higher Ct values (https://www.cdc.gov/vaccines/covid-19/health-departments/breakthrough-cases.html, 207 last accessed October 15, 2021). Therefore, while moderately lower sensitivity (91%) was observed with 208 the extraction-free method than conventional extraction, it still represents a viable alternative. The Omicron variant is surging rapidly right now with increasing interest and concern. However, 224 this study was performed before the Omicron variant was detected for the first time in the population. 225

Although the Allplex SARS-CoV-2 Master Assay for screening of SARS-CoV-2 and Omicron variant and 226

Novaplex SARS-CoV-2 Variants VII Assay for identification of Omicron-specific mutations (Seegene 227

Technologies, Walnut Creek, CA) are available now, these two new assays are not within the scope of 228 evaluation in this study. However, a summary table (Supplementary Table S3) 

Novel SARS-CoV-2 variants: the 248 pandemics within the pandemic

Analysis and Structural Dynamics of the Emergence 250 of Genetic Variants of SARS-CoV-2

SARS-CoV-2 variants, spike mutations and immune escape

Increased transmissibility and global 256 spread of SARS-CoV-2 variants of concern as at

Estimated transmissibility and 260 impact of SARS-CoV-2 lineage B.1.1.7 in England

Possible future waves of SARS-CoV-2 infection generated by variants of concern with a range 263 of characteristics

Tiled-ClickSeq for targeted 267 sequencing of complete coronavirus genomes with simultaneous capture of RNA recombination 268 and minority variants

Use of a simplified sample processing step without RNA 273 extraction for direct SARS-CoV-2 RT-PCR detection

CoV-2 detection by direct rRT-PCR without RNA extraction

Massive and rapid COVID-19 testing 278 is feasible by extraction-free SARS-CoV-2 RT-PCR

Direct RT-qPCR detection of SARS-CoV-2 RNA from patient 282 nasopharyngeal swabs without an RNA extraction step

Extraction-free methods for the detection of SARS-CoV-2 284 by reverse transcription-PCR: A comparison with the cepheid xpert xpress SARS-CoV-2 assay 285 across two medical centers

Extracted RNA